Clinical trials: Wilson Disease
Mowat-Wilson Syndrome, Dental Caries
Oral Health, Dento-facial Condition and OHRQoL in Subjects With Mowat-Wilson Syndrome: an Epidemiologic Study.
Mowat-Wilson Syndrome (MWS) is a rare syndrome characterized by the presence of facial gestalt and delayed psychomotor development, variably associated with intellectual disability, epilepsy, Hirschsprung's disease (HSCR) and…
- Conditions
- Mowat-Wilson Syndrome, Dental Caries, Periodontal Diseases, Sleep Related Breathing Disorder
- Trial name
- ORALMOWAT26 (NCT07476417)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Milan
Wison's Disease
Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.
The purpose of this study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese.
- Trial name
- NCT00212368
- Testing
- Zinc acetate
- Sponsor
- Nobelpharma
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Clinical Outcome in WILSON Disease
Clinical Profile and Out Come of Children With Wilson's Disease
Clinical profile and out come of Children with Wilson's disease :A single tertiary center study
- Trial name
- NCT05792319
- Testing
- 24 hour copper in urine and liver function test
- Volunteers
- 20 people
- Sponsor
- Assiut University
Wilson Disease
Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease
The primary objective of the study is to determine the relevance and appropriateness of outcome assessments, including biomarkers, within the Wilson disease population to inform study design and endpoint selection for future…
- Trial name
- NCT04531189
- Where
- 6 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Ultragenyx Pharmaceutical Inc